Emily C L Wong

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 7

Top Topics

Juvenile Idiopathic Arthritis

Top Venues

The American journal of gastroenterology

This page only lists publications with an associated author ORCID identifier.

Publications

Neeraj Narula, Emily C L Wong, Parambir S Dulai, John K Marshall, Vipul Jairath, Walter Reinisch
Delayed Ustekinumab and Adalimumab Responders Have Similar Outcomes as Early Responders in Biologic-Naïve Crohn's Disease. The American journal of gastroenterology 119 (7) (2024)
Neeraj Narula, Emily C L Wong, Parambir S Dulai, John K Marshall, Vipul Jairath, Walter Reinisch
Delayed Ustekinumab and Adalimumab Responders Have Similar Outcomes as Early Responders in Biologic-Naïve Crohn's Disease. The American journal of gastroenterology (2024)
Neeraj Narula, Emily C L Wong, Parambir S Dulai, John K Marshall, Vipul Jairath, Walter Reinisch
Delayed Ustekinumab and Adalimumab Responders Have Similar Outcomes as Early Responders in Biologic-Naïve Crohn's Disease. The American journal of gastroenterology 119 (7) (2024)
Neeraj Narula, Emily C L Wong, Parambir S Dulai, John K Marshall, Vipul Jairath, Walter Reinisch
Delayed Ustekinumab and Adalimumab Responders Have Similar Outcomes as Early Responders in Biologic-Naïve Crohn's Disease. The American journal of gastroenterology (2024)
Neeraj Narula, Emily C L Wong, Parambir S Dulai, John K Marshall, Vipul Jairath, Walter Reinisch
Delayed Ustekinumab and Adalimumab Responders Have Similar Outcomes as Early Responders in Biologic-Naïve Crohn's Disease. The American journal of gastroenterology 119 (7) (2024)
Neeraj Narula, Emily C L Wong, Parambir S Dulai, John K Marshall, Vipul Jairath, Walter Reinisch
Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease. The American journal of gastroenterology 117 (7) (2022)
Neeraj Narula, Emily C L Wong, John K Marshall, Vipul Jairath, Parambir S Dulai, Walter Reinisch
Long-Term Outcomes of Early vs Delayed Responders to Vedolizumab and Adalimumab: A Post Hoc Analysis of the VARSITY Study. The American journal of gastroenterology (2022)